Equities analysts expect that Genprex Inc (NASDAQ:GNPX) will post earnings per share (EPS) of ($0.21) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Genprex’s earnings. Genprex posted earnings per share of ($0.45) in the same quarter last year, which suggests a positive year over year growth rate of 53.3%. The company is scheduled to issue its next earnings results on Tuesday, August 27th.
On average, analysts expect that Genprex will report full year earnings of ($0.87) per share for the current year. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Genprex.
Genprex (NASDAQ:GNPX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03).
Shares of GNPX stock traded up $0.04 during mid-day trading on Wednesday, hitting $0.95. 28,428 shares of the stock were exchanged, compared to its average volume of 39,568. The stock’s fifty day simple moving average is $1.02 and its two-hundred day simple moving average is $1.46. The stock has a market capitalization of $15.14 million, a price-to-earnings ratio of -1.06 and a beta of 1.49. Genprex has a 12-month low of $0.64 and a 12-month high of $2.75.
A hedge fund recently bought a new stake in Genprex stock. Citadel Advisors LLC bought a new stake in shares of Genprex Inc (NASDAQ:GNPX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned 0.20% of Genprex as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.65% of the company’s stock.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Recommended Story: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.